Drug Type Biological products |
Synonyms OMO 103, OMO-103, OMO103 |
Target |
Mechanism MYC inhibitors(Myc proto-oncogene protein inhibitors) |
Inactive Indication |
Originator Organization Peptomyc SLStartup |
Active Organization Peptomyc SLStartup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Colorectal Cancer | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Pancreatic Cancer | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Pancreatic Ductal Adenocarcinoma | Phase 1 | ES | Peptomyc SLStartup | 31 Aug 2023 |
Secondary malignant neoplasm of pancreas | Phase 1 | ES | Peptomyc SLStartup | 31 Aug 2023 |
Phase 1/2 | 22 | oygzijgvgc(ealvnzmghz) = qptxruuoel wgerylujzr (xxsopuapfk, yabkallbot - raacdvujcn) View more | - | 25 Apr 2024 | |||
NCT04808362 (Pubmed) Manual | Phase 1 | Advanced Malignant Solid Neoplasm MYC Expression | 19 | daaumkycaf(ielvaudmdw) = The most common adverse events were grade 1 infusion-related reactions, occurring in ten patients. One dose-limiting toxicity occurred at DL5. btohapxcra (itgvzlmejx ) | Positive | 01 Mar 2024 | |
NCT04808362 (ENA2022) Manual | Phase 1 | 22 | iwtkcmfzfr(edwhgjqmrd) = jokdnuydqu kzrypevlwz (gdkbtzopyc ) View more | Positive | 01 Nov 2022 |